Global Tuberculosis Testing Market - 2022-2029

Market Overview

The Tuberculosis Testing Market size was valued at US$ 1,337.10 million in 2021 and is estimated to reach US$ 2058.0 million by 2029, growing at a CAGR of 6.0% during the forecast period (2022-2029).

Tuberculosis (TB) is a communicable disease that is a major cause of ill health, one of the top 10 causes of death worldwide, and the leading cause of death from a single infectious agent. It is caused by the bacillus Mycobacterium tuberculosis, which is spread when sick people with TB expel bacteria into the air, for example, by coughing. It typically affects the lungs (pulmonary TB) but can also affect other sites. About a quarter of the world's population is infected with M. tuberculosis and thus at risk of developing TB disease. Tuberculosis testing can be defined as the most commonly used diagnostic tool for tuberculosis. With a timely diagnosis and treatment with first-line antibiotics for 6 months, most people who develop TB can be cured, and onward transmission of infection curtailed. The number of TB cases occurring each year can also be driven down by reducing the prevalence of health-related risk factors for TB providing preventive treatment to people.

Market Dynamics

The tuberculosis testing market is driven by the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing government initiatives and rising awareness in the emerging market.

Increasing burden of tuberculosis are expected to drive market growth.

The market is driven by the increasing number of coronavirus cases, increasing the number of tuberculosis patients. According to the World Health Organization (WHO), in 2020, an estimated 10 million people fell ill with tuberculosis (TB) worldwide, 5.6 million men, 3.3 million women and 1.1 million children, which is more than half of global TB deaths. Factors propelling the market's growth include the increasing burden of tuberculosis and multidrug-resistant tuberculosis, increasing R&D investments, intensive product pipelines, and increasing government initiatives in the emerging markets. The landscape of TB diagnostics has changed dramatically during the past ten years. Moreover, in response to the WHO Global TB program, it has implemented a systematic and dynamic process used to evaluate technologies and develop policies, which has enhanced the market's growth.

The prevalence rate of tuberculosis is also increasing every year, along with the number of government awareness programs that influence people to opt for diagnostic tests (like radiographic tests), which are expected to drive the market during the forecast period. The market is also expected to witness growth as there is an opportunity for players in the market to accelerate their pipeline diagnostic products' market approval by spurring the fundamental research in TB. Additionally, technological developments in genomics and proteomics can be leveraged by diagnostic providers to hasten product development in TB diagnostics.

The increasing screening rate in the high burden regions, affordability of diagnostics, advanced methodologies, faster clinical decisions, and reduction in mortality rate are the focal areas of development. Improved preventive and curative diagnosis rates are the results of these initiatives. This has led to a subsequent upsurge in demand for diagnostic tests and the TB diagnostics market. Furthermore, the government and independent healthcare organizations have undertaken initiatives to control this infectious disease's proliferation. Creating awareness about the importance of diagnosis is vital in increasing the screening and diagnosis rates, further helping the TB diagnostics market flourish. This factor is driving the growth of the market in the forecast period. For instance, the Revised National Tuberculosis Control Program (RNTCP) in India focuses on performing TB screening and providing greater access to treatment through free diagnosis & treatment programs. Besides, private-public partnerships under this program are boosting the diagnosis rate.

Population above the age of 60 is the target population for the TB diagnostics market as this demographic is susceptible to infectious diseases. The growing geriatric population base, as a result, is driving the growth of the market.

Drug resistance with tuberculosis drugs is expected to hamper the market growth.

However, drug resistance in tuberculosis is one of the primary concerns for healthcare professionals as improper treatment due to wrong drug regimens and incorrect dosage forms lead to drug resistance in TB patients undergoing treatment, restraining the market's growth.

Industry Analysis

The global tuberculosis testing market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory Analysis, Supply Chain Analysis, Pricing Analysis, Product Innovation, Unmet Needs.

Segment Analysis

Test type segment is expected to hold the largest market share in global Tuberculosis Testing market

The global tuberculosis testing market is segmented on test type by Cytokine Detection Assay, Nuclеic Acid Tеsting, Detection of Latent Infection, Culturе Basеd Tеsts, Drug Suscеptibility Tеsting, and Othеrs. The Nuclеic Acid Tеsting segment held the largest market share due to its use as diagnostic tools for tuberculosis (TB) for many years, and which continue to be used. There are substantial advancements in the diagnosis of TB. Moreover, these tests have been commercially available in the United States for over two decades that offer better accuracy than other microscopy tests and even provide greater speed than culture-based tests. A nucleic acid test for tuberculosis (TB) is a molecular test used to detect the DNA (deoxyribonucleic acid) of Mycobacterium tuberculosis complex (MTBC) in sputum or other respiratory samples. Because the amount of DNA in a sample is minimal, NAA testing includes a step that amplifies (or copies) the genetic material. Polymerase Chain Reaction (PCR) is a common form of nucleic acid test used in laboratory diagnosis. Drug Suscеptibility Tеsting is expected to have positive market growth because they are cost-efficient and easy-to-perform. The high burden regions rely on these methodologies due to their financial and technical incapability to incorporate advanced technologies, thus contributing to its growth.

A Cytokine Detection Assay is usually employed to check for the specific cytokines being secreted. This is more a function of biochemistry research rather than a specific test for body functions. Cytokines and their receptors are under a great deal of research because of their role in disease control. It is worth noting that many cytokines have an opposing and sometimes complementary effect on each other; thereby, modulating the immune response's severity. Cytokine assays are used to identify which cytokines and their deficiencies are responsible for the cause of some autoimmune diseases.

A Detection of Latent Infection The goal of testing for LTBI is to identify individuals at increased risk for developing tuberculosis (TB) and, therefore, who would benefit from treatment of latent TB infection. Only those who would benefit from treatment should be tested, so a decision to test presupposes a decision to treat if the test is positive. This factor would drive the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global tuberculosis testing market

By region, the Tuberculosis Testing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Asia-Pacific dominated the global tuberculosis testing market and is expected to grow at the highest CAGR during the forecast period. The growth of the market in the region is attributed to tuberculosis's high burden and the rapid proliferation of this disease. The increasing prevalence of TB in Japan helps in the TB diagnostics market's growth. The high prevalence of TB creates an urgent demand for effective and quick diagnosis of the disease. Besides, in countries such as India, according to the recent budget announcement, the Government of India aims to eliminate tuberculosis by 2025, which is expected to act as one of the major factors for the growth of the Asia-Pacific market forecast period.

Infectious and Endemic Disease Control in China, RNTCP in India, and the National TB program in Afghanistan are the few programs planned by local healthcare agencies to contain the incidence and ensure equitable access to diagnosis. As per the WHO, countries such as India, China, Afghanistan, and Indonesia are priority regions for controlling this communicable disease.

Competitive Landscape

The global tuberculosis testing market is highly competitive, with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Thermo Fisher Scientific, Inc., Hologic Corporation, Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche AG, bioMerieux SA, Sanofi, Cepheid, Hain Lifescience GmbH, are the leading market players with significant market share.

Key Companies to Watch

Abbott Laboratories:

Overview: Abbott is American multinational company that develops medical devices and healthcare products. It was founded in 1888 and is headquartered in Illinois, United States. Their products and services include medical devices, diagnostics, nutritional products and branded generic medicines.

Product Portfolio:

The Abbott RealTime MTB assay is an in vitro polymerase chain reaction (PCR) assay for the qualitative detection of MTB complex DNA in smear positive or smear negative specimen of sputum or bronchial alveolar lavage and N-acetyl-L-cysteine (NALC)-prepared sediments prepared from sputum and broncial alveolar lavage collected from individuals suspected of having tuberculosis (TB).

The global tuberculosis testing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.